[go: up one dir, main page]

EP1192174A4 - Antagonistes des voies de signalisation bmp et tgf beta - Google Patents

Antagonistes des voies de signalisation bmp et tgf beta

Info

Publication number
EP1192174A4
EP1192174A4 EP00941398A EP00941398A EP1192174A4 EP 1192174 A4 EP1192174 A4 EP 1192174A4 EP 00941398 A EP00941398 A EP 00941398A EP 00941398 A EP00941398 A EP 00941398A EP 1192174 A4 EP1192174 A4 EP 1192174A4
Authority
EP
European Patent Office
Prior art keywords
smurf1
bmp
tgfβ
signalling
smurf2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00941398A
Other languages
German (de)
English (en)
Other versions
EP1192174A2 (fr
Inventor
Gerald H Thomsen
Jeffrey Wrana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HSC Research and Development LP
Research Foundation of the State University of New York
Original Assignee
HSC Research and Development LP
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HSC Research and Development LP, Research Foundation of the State University of New York filed Critical HSC Research and Development LP
Publication of EP1192174A2 publication Critical patent/EP1192174A2/fr
Publication of EP1192174A4 publication Critical patent/EP1192174A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des éléments uniques de la famille Hect des ubiquitine ligases qui ciblent spécifiquement des protéines Smad spécifiques des voies de signalisation BMP et TGFβ/activine. Les nouvelles ligases ont été appelées Smurf1 et Smurf2. Elles interagissent directement avec les protéines Smad1 et 5 et avec Smad7, respectivement, et régulent l'ubiquitination, le renouvellement et l'activité de protéines Smad et d'autres protéines de ces voies de signalisation. Smurf1 intervient dans les réponses biologiques à BMP, mais pas dans la signalisation d'activine. Dans des embryons d'amphibiens, Smurf1 inhibe les signaux de BMP endogène, ce qui entraîne une formation de motif et une spécification de destin cellulaire modifiées dans le mésoderme et l'ectoderme. La présente invention concerne un lien régulatoire unique entre la voie d'ubiquitination et la régulation de la détermination du destin cellulaire par la superfamille des TGFβ au cours du développement embryonnaire. De ce fait, Smurf1 constitue un régulateur négatif de la transduction de signal Smad1 : en ciblant Smad1, Smurf1 bloque la signalisation BMP. Dans des cellules de mammifère, Smurf2 supprime la signalisation TGFβ, et, chez le xénope, bloque la formation de mésoderme dorsal et provoque une troncature antérieure des embryons. Smurf2 forme un complexe stable avec Smad7, ce qui entraîne une dégradation et une diminution de la signalisation TGFβ/activine.
EP00941398A 1999-06-11 2000-06-12 Antagonistes des voies de signalisation bmp et tgf beta Withdrawn EP1192174A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13896999P 1999-06-11 1999-06-11
US138969P 1999-06-11
PCT/US2000/016250 WO2000077168A2 (fr) 1999-06-11 2000-06-12 ANTAGONISTES DES VOIES DE SIGNALISATION BMP ET TGF$g(b)

Publications (2)

Publication Number Publication Date
EP1192174A2 EP1192174A2 (fr) 2002-04-03
EP1192174A4 true EP1192174A4 (fr) 2002-08-28

Family

ID=22484504

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00941398A Withdrawn EP1192174A4 (fr) 1999-06-11 2000-06-12 Antagonistes des voies de signalisation bmp et tgf beta

Country Status (7)

Country Link
EP (1) EP1192174A4 (fr)
JP (1) JP2003502064A (fr)
CN (1) CN100379752C (fr)
AU (1) AU782355B2 (fr)
CA (1) CA2376675A1 (fr)
IL (1) IL147005A0 (fr)
WO (1) WO2000077168A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7358056B1 (en) 1999-08-30 2008-04-15 Signal Pharmaceuticals Methods for modulating signal transduction mediated by TGF-β and related proteins
WO2003030924A1 (fr) * 2001-10-09 2003-04-17 Osteoscreen, Inc. Identification de modulateurs specifique de la formation osseuse
EP1639008A1 (fr) * 2003-07-01 2006-03-29 VIB vzw Tnf recepteur 2 ubiquitine et ses utilisations
US7901874B2 (en) * 2003-09-11 2011-03-08 Hubit Genomix, Inc. Methods for identifying agents for preventing or treating proliferative diseases, and for inhibiting extracellular matrix or α1 type IV collagen
GB0526664D0 (en) * 2005-11-30 2006-02-08 Plasticell Ltd Method
US8898056B2 (en) 2006-03-01 2014-11-25 Qualcomm Incorporated System and method for generating a separated signal by reordering frequency components
WO2008101951A1 (fr) 2007-02-21 2008-08-28 Vib Vzw Thérapie combinatoire par tnf et alfa-galactosylcéramide
EP2167976A2 (fr) * 2007-05-29 2010-03-31 President And Fellows Of Harvard College Molécules impliquées dans la régulation de l'activité des ostéoblastes et des ostéoclastes, et leurs méthodes d'utilisation
WO2011088163A1 (fr) 2010-01-14 2011-07-21 President And Fellows Of Harvard College Procédés de modulation de remodélisation et structuration squelettiques par modulation de l'activité de shn2, de l'activité de shn3 ou de l'activité combinée de shn2 et de shn3
TWI714528B (zh) * 2014-05-14 2021-01-01 瑞士商諾華公司 甲醯胺衍生物
TW201623288A (zh) * 2014-05-14 2016-07-01 諾華公司 甲醯胺衍生物
KR102360028B1 (ko) * 2014-12-26 2022-02-08 삼성전자주식회사 Smurf2의 저해제를 포함하는 세포 또는 개체의 노화를 감소시키기 위한 조성물 및 그의 용도
CN110196326A (zh) * 2019-06-05 2019-09-03 武汉合研生物医药科技有限公司 一种TGFβR1（T204D）酶活性的快速检测方法及其应用
CN110592032B (zh) * 2019-10-14 2021-04-13 北京理工大学 泛素连接酶Smurf1突变体、编码基因及用途
EP4242318B1 (fr) 2021-01-21 2025-11-12 Cellid Co., Ltd. Nouveau vecteur adénoviral ne comprenant pas d'adénovirus compétent de réplication et utilisation associée
CN117721131A (zh) * 2023-12-19 2024-03-19 吉林大学 一种重组骨形态发生蛋白突变体的制备方法和应用
CN119386159B (zh) * 2024-12-31 2025-04-22 温州医科大学 一种mRNA-多肽复合物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012962A1 (fr) * 1995-10-04 1997-04-10 Cold Spring Harbor Laboratory Ubiquitine ligases et utilisations associees

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001507239A (ja) * 1997-05-20 2001-06-05 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｓｍａｄ２のリン酸化とｓｍａｄ４との相互作用
US5976849A (en) * 1998-02-05 1999-11-02 Zeneca Limited Human E3 ubiquitin protein ligase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012962A1 (fr) * 1995-10-04 1997-04-10 Cold Spring Harbor Laboratory Ubiquitine ligases et utilisations associees

Also Published As

Publication number Publication date
CN1409722A (zh) 2003-04-09
AU782355B2 (en) 2005-07-21
AU5610700A (en) 2001-01-02
CA2376675A1 (fr) 2000-12-21
IL147005A0 (en) 2002-08-14
EP1192174A2 (fr) 2002-04-03
WO2000077168A2 (fr) 2000-12-21
CN100379752C (zh) 2008-04-09
WO2000077168A3 (fr) 2001-05-03
JP2003502064A (ja) 2003-01-21

Similar Documents

Publication Publication Date Title
EP1192174A4 (fr) Antagonistes des voies de signalisation bmp et tgf beta
Coyle-Rink et al. Developmental expression of Wnt signaling factors in mouse brain
Borgs et al. Period 2 regulates neural stem/progenitor cell proliferation in the adult hippocampus
Zhao et al. Smurf1 inhibits osteoblast differentiation and bone formation in vitro and in vivo
Yamamura et al. A heart segmental defect in the anterior-posterior axis of a transgenic mutant mouse
Shirakabe et al. Roles of Meltrin β/ADAM19 in the processing of neuregulin
Allen et al. Hedgehog signaling regulates sebaceous gland development
Beck et al. Extraembryonic proteases regulate Nodal signalling during gastrulation
Botchkarev et al. BMP signaling in the control of skin development and hair follicle growth
Basson et al. Specific regions within the embryonic midbrain and cerebellum require different levels of FGF signaling during development
Campbell et al. Annexin A6 interacts with p65 and stimulates NF‐κB activity and catabolic events in articular chondrocytes
Sahara et al. Sp8 exhibits reciprocal induction with Fgf8 but has an opposing effect on anterior-posterior cortical area patterning
Ito et al. Receptor‐regulated and inhibitory Smads are critical in regulating transforming growth factorβ–mediated Meckel's cartilage development
Gorski et al. Skeletal‐specific expression of Fgd1 during bone formation and skeletal defects in faciogenital dysplasia (FGDY; Aarskog syndrome)
Monteiro et al. Real time monitoring of BMP Smads transcriptional activity during mouse development
Hosokawa et al. Epithelial‐specific requirement of FGFR2 signaling during tooth and palate development
Su et al. The evolutionally conserved activity of Dapper2 in antagonizing TGF‐ß signaling
Ito et al. Overexpression of Smad2 reveals its concerted action with Smad4 in regulating TGF-β-mediated epidermal homeostasis
Kablar et al. Invited Reviews-Skeletal muscle development in the mouse embryo
EP3407901A1 (fr) Expansion et différenciation des cellules de support de l'oreille interne, et méthodes d'utilisation de ces dernières
Liu et al. Transforming growth factor β2, but not β1 and β3, is critical for early rat lung branching
Muraoka et al. Mesenchymal expression of nuclear factor-κB inhibits epithelial growth and branching in the embryonic chick lung
US20070036769A9 (en) BMP pathway methods and compositions
Gos et al. Early neonatal and postweaning social emotional deprivation interferes with the maturation of serotonergic and tyrosine hydroxylase-immunoreactive afferent fiber systems in the rodent nucleus accumbens, hippocampus and amygdala
Das et al. Drosophila dSmad2 and Atr‐I transmit activin/TGFβ signals

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020111

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20020716

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07H 21/04 A, 7C 12N 15/00 B, 7C 07K 14/00 B, 7C 12N 9/00 B

17Q First examination report despatched

Effective date: 20050524

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100105